Clinical Trial Update: An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L [Phase 2]

View source ↗

Summary

This entry describes a Phase II investigator-initiated, multicenter trial evaluating alternating bortezomib-based regimens with daratumumab, followed by daratum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasma Cell Leukemia

Drugs mentioned

• DARZALEX (daratumumab)
• Velcade (bortezomib)

Snippet

Sponsor: Hellenic Society of Hematology | Conditions: Primary Plasma Cell Leukemia | Phase 2 | Status: RECRUITING